Viking Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Viking Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. 

CEO
Brian Lian
CEOBrian Lian
Employees
36
Employees36
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2012
Founded2012
Employees
36
Employees36

VKTX Key Statistics

Market cap
3.55B
Market cap3.55B
Price-Earnings ratio
-14.82
Price-Earnings ratio-14.82
Dividend yield
Dividend yield
Average volume
3.40M
Average volume3.40M
High today
$32.20
High today$32.20
Low today
$31.20
Low today$31.20
Open price
$31.70
Open price$31.70
Volume
1.58M
Volume1.58M
52 Week high
$43.15
52 Week high$43.15
52 Week low
$18.92
52 Week low$18.92

Stock Snapshot

The current Viking Therapeutics(VKTX) stock price is $31.64, with a market capitalization of 3.55B. The stock trades at a price-to-earnings (P/E) ratio of -14.82.

On 2026-01-28, Viking Therapeutics(VKTX) stock traded between a low of $31.20 and a high of $32.20. Shares are currently priced at $31.64, which is +1.4% above the low and -1.7% below the high.

Viking Therapeutics(VKTX) shares are trading with a volume of 1.58M, against a daily average of 3.4M.

During the past year, Viking Therapeutics(VKTX) stock moved between $18.92 at its lowest and $43.15 at its peak.

During the past year, Viking Therapeutics(VKTX) stock moved between $18.92 at its lowest and $43.15 at its peak.

VKTX News

Simply Wall St 4d
Viking Therapeutics Is Down 5.0% After Phase 2 VK2735 Data And Phase 3 Updates – Has The Bull Case Changed?

In January 2026, Viking Therapeutics reported published Phase 2 VENTURE trial data for its dual GLP-1/GIP agonist VK2735, showing statistically significant weig...

Viking Therapeutics Is Down 5.0% After Phase 2 VK2735 Data And Phase 3 Updates – Has The Bull Case Changed?
Simply Wall St 6d
Assessing Viking Therapeutics Valuation After VK2735 Phase 2 Success And Phase 3 Trial Progress

Advertisement Why VK2735’s latest trial results matter for Viking Therapeutics (VKTX) Viking Therapeutics (VKTX) is back in focus after publishing Phase 2 VEN...

Assessing Viking Therapeutics Valuation After VK2735 Phase 2 Success And Phase 3 Trial Progress

Analyst ratings

94%

of 18 ratings
Buy
94.4%
Hold
5.6%
Sell
0%

People also own

Based on the portfolios of people who own VKTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.